Compatibility Assessment of Novel Orodispersible Film Vehicle for Personalized Medicine with Selected Active Pharmaceutical Ingredients
Journal of Personalized Medicine · 31.10.2023 · 13 (11) · 1565
DOI: 10.3390/jpm13111565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 31.10.2023. Verfasst von Hudson C Polonini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Fagron BV, Fascinatio Boulevard 350, 3065 WB Rotterdam, The Netherlands. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Orodispersible films (ODFs) are solid pharmaceutical forms for rapid local or systemic release of active ingredients. They are formed by a water-soluble polymer film that hydrates rapidly, adhering and dissolving immediately when placed on the tongue or in the oral cavity. In this paper, we describe the compatibility and disintegration times of compounded ODFs using OrPhylloTM, a new ready-to-use-vehicle, and APIs from different pharmacological classes, such as 5-hydroxytryptophan (5-HTP) 50 mg, bromopride 5 mg, coenzyme Q10 20 mg, melatonin 3 mg, resveratrol 5 mg, tadalafil 10 mg, vitamin B12 1 mg, or vitamin D3 2000 UI. ODFs were compounded and, subsequently, the samples were assayed using HPLC at initial (t = 0), 7 days (t = 7), 14 days (t = 14), 30 days (t = 30), 60 days (t = 60), 90 days (t = 90), 120 days (t = 120), 150 days (t = 150), and 180 days (t = 180) after compounding. Given the percentage of recovery of the APIs within the films, the beyond-use date of the final products (API + vehicle) was at least 90 days for vitamin D3, 150 days for bromopride and 5-HTP, and 180 days for coenzyme Q10, tadalafil, vitamin B12, resveratrol, and melatonin, when stored at room temperature. The average disintegration time was 46.22 s. This suggests that the OrPhylloTM vehicle is suitable for compounding ODFs with APIs from different pharmacological classes, with good compatibility and fast disintegration.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Fagron BV, Fascinatio Boulevard 350, 3065 WB Rotterdam, The Netherlands.
- Research and Innovation Center for Health Sciences, Federal University of Juiz de Fora (UFJF), Juiz de Fora 36038, MG, Brazil.
ORCID-Profile: Hudson C Polonini, Nádia R B Raposo
Zitieren
APA
Polonini, H. C., Ferreira, A. O., Raposo, N. R. B., da Silva, P. J. L. C., & Brandão, M. A. F. (2023). Compatibility Assessment of Novel Orodispersible Film Vehicle for Personalized Medicine with Selected Active Pharmaceutical Ingredients. Journal of Personalized Medicine, 13(11), 1565. https://doi.org/10.3390/jpm13111565
Vancouver
Polonini HC, Ferreira AO, Raposo NRB, da Silva PJLC, Brandão MAF. Compatibility Assessment of Novel Orodispersible Film Vehicle for Personalized Medicine with Selected Active Pharmaceutical Ingredients. Journal of Personalized Medicine. 2023;13(11):1565. doi:10.3390/jpm13111565
BibTeX
@article{Polonini2023,
author = {Polonini, Hudson C and Ferreira, Anderson O and Raposo, Nádia R B and da Silva, Paulo José L C and Brandão, Marcos Antônio F},
title = {Compatibility Assessment of Novel Orodispersible Film Vehicle for Personalized Medicine with Selected Active Pharmaceutical Ingredients},
journal = {Journal of Personalized Medicine},
year = {2023},
volume = {13},
number = {11},
pages = {1565},
doi = {10.3390/jpm13111565}
}
EUVIMED